All In Biotech

Drug Trial Radar · NCT07869134

Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis

A Proof-of-Concept Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Two Dose Levels of FT2109 in Biologic Naïve and Biologic Experienced Participants With Active Psoriatic Arthritis (PsA)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Oct 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Forward TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have been treated previously with advanced therapy and who may be on stable background therapy. In this study, researchers will look at different doses of FT2109 compared to placebo (a treatment with no active study drug in it). Researchers will try to learn if at least one of the study doses of FT2109 works better than placebo to treat PsA symptoms.

Conditions

  • Psoriatic Arthritis (PsA)

Interventions

  • FT2109 Dosing Regimen 1Drug

    Administered daily for 12 weeks

  • FT2109 Dosing Regimen 2Drug

    Administered daily for 12 weeks

  • Matching PlaceboDrug

    Administered daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieved an American College of Rheumatology (ACR) 20 response at Week 12Time frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.